D
Revolution Medicines, Inc. RVMD
$96.95 -$1.25-1.27% NASDAQ
Recommendation
Prev Close
$96.95
Volume
609
Avg Vol (90D)
3,034,362
Market Cap
$18.74B
Dividend & Yield
--
52-Week Range
$29.17 - $124.49
P/E (TTM)
--
EPS (TTM)
-$5.18
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Revolution Medicines price target raised to $122 from $92 at JPMorgan
2/2/2026 - TipRanks Financial Blog
Did RMC-5127's First-in-Human Trial Launch Just Shift Revolution Medicines' (RVMD) Investment Narrative?
2/2/2026 - Simply Wall St
How Investors May Respond To Merck (MRK) Prioritizing Oncology Partnerships Over Mega-Deals
2/1/2026 - Simply Wall St
Knights of Columbus Asset Advisors LLC Takes $587,000 Position in Revolution Medicines, Inc. $RVMD
2/1/2026 - MarketBeat
Merck (MRK) Valuation Check As New Oncology Deals With Eikon And Guardant Reshape Its Cancer Strategy
1/31/2026 - Simply Wall St
Analysts Conflicted on These Healthcare Names: Revolution Medicines (RVMD), Roche Holding AG (OtherRHHVF) and Incyte (INCY)
1/31/2026 - TipRanks Financial Blog
Merck Ends Revolution Talks As Oncology Focus And Valuation Take Center Stage
1/30/2026 - Simply Wall St
Interesting RVMD Put And Call Options For May 15th
1/30/2026 - Nasdaq News: Stocks
Interesting RVMD Put And Call Options For May 15th
1/30/2026 - Stock Options Channel
Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), Neurocrine (NBIX)
1/29/2026 - TipRanks Financial Blog
Revolution Medicines (RVMD) Initiates First Human Trial for RMC-5127
1/29/2026 - GuruFocus
Revolution Medicines doses first patient in trial evaluating RMC-5127
1/29/2026 - The Fly
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) ...
1/29/2026 - GuruFocus
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor
1/29/2026 - Globe Newswire
Revolution Medicines (RVMD, $97.33) Stochastic Oscillator left the oversold zone on January 28, 2026
1/29/2026 - Tickeron - Stocks
Merck Ends Revolution Bid And Leans On Oncology Partnerships And Discipline
1/29/2026 - Simply Wall St
Y Intercept Hong Kong Ltd Has $2.58 Million Stock Position in Revolution Medicines, Inc. $RVMD
1/28/2026 - MarketBeat
Merck Ends Revolution Talks While Valuation Signals Potential Investor Opportunity
1/28/2026 - Simply Wall St
Analysts' Top Healthcare Picks: CVS Health (CVS), Revolution Medicines (RVMD)
1/27/2026 - TipRanks Financial Blog
RVMD Stock Tumbles as MRK Reportedly Withdraws Buyout Offer
1/27/2026 - Zacks Investment Research
Oppenheimer Raises Price Target for Revolution Medicines (RVMD) to $150 RVMD Stock News
1/27/2026 - GuruFocus
Revolution Medicines (RVMD, $97.78) Moving Average Convergence Divergence (MACD) Histogram turned negative on January 26, 2026
1/27/2026 - Tickeron - Stocks
Revolution Medicines (RVMD, $97.78) RSI Indicator left the overbought zone on January 26, 2026
1/27/2026 - Tickeron - Stocks
Revolution Medicines price target raised by $75 at Oppenheimer, here's why
1/27/2026 - The Fly
Revolution Medicines (RVMD) Dives 16.9% as Merck Withdraws Takeover Plan
1/27/2026 - Insider Monkey
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$1.03B
EBIT (TTM)
-$1.04B
Net Income (TTM)
-$960.98M
Balance Sheet
Total Assets (Q)
$2.25B
Total Debt (Q)
$414.97M
Total Liabilities (Q)
$655.02M
Book Value Per Share (Q)
$8.42
Cash Flow
Cash from Operations (TTM)
-$761.79M
Cash from Investing (TTM)
-$349.73M
Cash from Financing (TTM)
$1.13B
Net Change in Cash (TTM)
$18.15M
Filings
Filing Date
Wednesday, November 5, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 23 and 27 (est)
Price History
Loading...
Beta
1.04
7-Day Total Return
-18.40%
30-Day Total Return
26.34%
60-Day Total Return
65.53%
90-Day Total Return
119.32%
Year to Date Total Return
22.69%
1-Year Total Return
125.73%
2-Year Total Return
249.37%
3-Year Total Return
262.57%
5-Year Total Return
116.41%
52-week Low
Apr 07, 2025 - $29.17
52-week High
Jan 16, 2026 - $124.49
Valuation
Market Cap
$18.74B - Large Cap
Enterprise Value
$17.23B
Price/Sales (TTM)
--
Price/Book (Q)
11.52
Dividends and Shares
Shares Outstanding
189.23M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.revmed.com
Phone Number
650 481 6801
Address
700 Saginaw Drive
Redwood City, CA 94063
Country
United States
Year Founded
2014
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of... more
NASDAQ 01/30/2026 4:00PM Eastern Quotes delayed